Quest Diagnostics
DGX
$227.90
+8.61%
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US, generating over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing. As the dominant player in the diagnostic testing industry with a national network of roughly 2,400 patient service centers, it holds a distinct competitive position as a scale-driven essential healthcare service provider. The current investor narrative centers on steady organic growth driven by an aging population and expanding test menus, coupled with margin expansion from operational efficiencies and strategic acquisitions. Recent attention has focused on the company's ability to sustain mid-single-digit revenue growth while improving profitability through cost controls and mix shift toward higher-margin esoteric testing.…
DGX
Quest Diagnostics
$227.90
Investment Opinion: Should I buy DGX Today?
Rating: Buy. Thesis: Quest Diagnostics offers a compelling combination of steady growth, strong cash flows, and a discounted valuation relative to peers, making it a solid core holding for healthcare exposure.
Supporting Evidence: The trailing PE of 19.56x is below the industry average of 22.0x, representing an 11% discount. Revenue grew 9.16% YoY in Q1 2026, accelerating from prior quarters. Operating margin improved to 13.8% from 13.0% a year ago, demonstrating cost discipline. Free cash flow yield of ~6.9% is attractive. The consensus analyst target of $223.94 implies 6.3% upside, with a high target of $245 offering 16.3%.
Risks & Conditions: Key risks include reimbursement cuts, volume deceleration, and margin pressure from wage inflation. This Buy rating would be downgraded to Hold if revenue growth falls below 5% or if the PE expands above 22x without earnings acceleration. It would be upgraded to Strong Buy if the stock pulls back to $190 (near the low target) or if growth sustains above 10%. Overall, the stock appears fairly valued relative to its history and peers, with a slight margin of safety given the free cash flow yield.
Sign up to view all
DGX 12-Month Price Forecast
Quest Diagnostics is well-positioned for steady gains given its accelerating revenue growth, discounted valuation, and strong cash generation. The low beta and defensive healthcare exposure make it a resilient choice in uncertain markets. The base case of 7-9% growth and stable margins supports a price near the average target. Upside could come from margin expansion or a re-rating, while downside is limited by the free cash flow yield and 52-week low support. I would upgrade to higher confidence if Q2 2026 revenue exceeds $2.95B or if the company announces a large share buyback.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Quest Diagnostics's 12-month outlook, with a consensus price target around $223.94 and implied upside of -1.7% versus the current price.
Average Target
$223.94
0 analysts
Implied Upside
-1.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$184 - $245
Analyst target range
Quest Diagnostics is covered by 16 analysts, with a consensus recommendation of 'Buy' (mean rating 2.17 on a 1-5 scale where 1 is Strong Buy). The average target price is $223.94, implying approximately 6.3% upside from the current price of $210.68. The distribution shows a bullish tilt, with no sell ratings and a majority of buy or overweight ratings. Recent ratings from firms like Barclays (Overweight), Jefferies (Buy), and Mizuho (Outperform) reinforce positive sentiment, while Baird and Truist maintain Neutral/Hold. The target range spans from $184.00 (low) to $245.00 (high), representing a 33% spread between the low and high, indicating moderate uncertainty. The high target of $245.00 implies 16.3% upside and likely assumes continued margin expansion and revenue growth from new test launches and acquisitions. The low target of $184.00 suggests downside risk from potential reimbursement cuts or volume softness. The wide spread reflects differing views on the pace of growth and margin trajectory, but the overall consensus is constructive.
Bulls vs Bears: DGX Investment Factors
Quest Diagnostics presents a balanced risk/reward profile. The bull case is supported by accelerating revenue growth (9.16% YoY), a discounted valuation (PE 19.56x vs industry 22.0x), strong free cash flow ($1.326B TTM), and a consensus Buy rating with 6.3% upside to the average target. However, the bear case highlights modest growth expectations (PEG 1.43x), proximity to the 52-week high, elevated short interest (4.23 days), and a debt-to-equity ratio near 1.0. The single most important tension is whether the company can sustain its revenue acceleration and margin expansion to justify the current valuation; if growth decelerates, the stock could revert to the low end of its target range ($184), while continued momentum could drive it toward the high target ($245). Currently, the evidence slightly favors the bull case given the valuation discount and strong cash flows.
Bullish
- Strong Revenue Growth Acceleration: Q1 2026 revenue grew 9.16% YoY to $2.895B, accelerating from 5.8% in Q4 2025 and 6.0% in Q3 2025, driven by volume increases and mix shift toward higher-value esoteric testing.
- Attractive Valuation vs. Peers and History: Trailing PE of 19.56x is below the industry average of 22.0x (11% discount) and near the lower end of its 5-year range (6.5x-44x), suggesting the stock is not overvalued.
- Consensus Buy Rating with Upside: 16 analysts rate it a Buy (mean 2.17/5), with an average target of $223.94 implying 6.3% upside. High target of $245 suggests 16.3% potential upside.
- Robust Free Cash Flow Generation: TTM free cash flow of $1.326B yields ~6.9% of market cap, supporting dividends (1.83% yield, 35.6% payout) and strategic acquisitions.
Bearish
- Modest Growth Profile Limits Upside: Revenue growth of 9.16% is solid but not explosive; PEG ratio of 1.43x suggests the stock is fairly valued, limiting multiple expansion potential.
- Trading Near 52-Week High: At $210.68, the stock is at 96.1% of its 52-week high of $219.20, leaving limited near-term upside and increasing risk of a pullback.
- High Short Ratio Indicates Skepticism: Short ratio of 4.23 days suggests elevated bearish sentiment, potentially reflecting concerns about reimbursement cuts or volume softness.
- Debt-to-Equity Near 1.0: Debt-to-equity of 0.96 is manageable but not conservative; interest expense of $63M in Q1 2026 consumes a portion of operating income.
DGX Technical Analysis
Quest Diagnostics is in a sustained uptrend, with the stock up 25.27% over the past year, significantly outperforming the S&P 500's 18.35% gain. The current price of $210.68 sits at 96.1% of its 52-week range ($165.30 to $219.20), indicating the stock is trading near its highs, reflecting strong momentum but also potential overextension. The 52-week low of $165.30 provides a clear support level, while the high of $219.20 represents immediate resistance. Short-term momentum is accelerating, with the stock gaining 6.53% over the past month and 8.03% over the past three months, both outpacing the S&P 500's 0.31% and 4.67% gains, respectively. The 1-month relative strength of 6.22% versus the market confirms strong near-term buying pressure. However, the 1-year trend shows a more gradual ascent, suggesting the recent acceleration could be a momentum surge rather than a fundamental shift. The stock's beta of 0.571 indicates it is significantly less volatile than the market, meaning it tends to move less than the S&P 500, which is attractive for risk-averse investors. A breakout above the 52-week high of $219.20 would signal a continuation of the uptrend, while a breakdown below the $165.30 low would be a bearish reversal. The current price is well above the 52-week low, suggesting strong support, but the proximity to the high means resistance is near.
Beta
0.57
0.57x market volatility
Max Drawdown
-11.9%
Largest decline past year
52-Week Range
$166-$238
Price range past year
Annual Return
+33.7%
Cumulative gain past year
| Period | DGX Return | S&P 500 |
|---|---|---|
| 1m | +15.6% | +0.6% |
| 3m | +16.1% | +3.4% |
| 6m | +25.9% | +7.1% |
| 1y | +33.7% | +16.4% |
| ytd | +31.1% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DGX Fundamental Analysis
Quest Diagnostics' revenue trajectory is solidly growing, with Q1 2026 revenue of $2.895 billion, up 9.16% year-over-year from $2.652 billion in Q1 2025. This marks an acceleration from the 5.8% YoY growth in Q4 2025 and the 6.0% growth in Q3 2025, driven by volume increases and mix shift toward higher-value esoteric testing. The company's revenue has grown sequentially from $2.397 billion in Q2 2024 to $2.895 billion in Q1 2026, reflecting consistent expansion. The diagnostic information services segment, which accounts for virtually all revenue, continues to benefit from an aging population and increased healthcare utilization. Profitability is robust, with net income of $252 million in Q1 2026, up from $220 million in Q1 2025, and a net margin of 8.7%, slightly improved from 8.3% a year ago. Gross margin has remained stable around 32.5-33.7% over the past year, while operating margin improved to 13.8% in Q1 2026 from 13.0% in Q1 2025, reflecting cost discipline. The company is consistently profitable with a trailing PE of 19.56x and a forward PE of 18.05x, indicating expected earnings growth. The balance sheet is healthy, with a debt-to-equity ratio of 0.96, manageable leverage, and a current ratio of 1.04, indicating adequate liquidity. Free cash flow generation is strong, with TTM free cash flow of $1.326 billion, translating to a free cash flow yield of approximately 6.9% based on the current market cap of $19.26 billion. ROE stands at 13.8%, reflecting efficient capital use. The company generates sufficient cash to fund operations and dividends, with a payout ratio of 35.6% and a dividend yield of 1.83%.
Quarterly Revenue
$2.9B
2026-03
Revenue YoY Growth
+9.2%
YoY Comparison
Gross Margin
32.5%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DGX Overvalued?
Since net income is positive, the primary valuation metric is the PE ratio. The trailing PE is 19.56x, while the forward PE is 18.05x, indicating the market expects earnings growth of about 8.4% over the next year. The gap between trailing and forward PE suggests modest growth expectations are already priced in. Compared to the industry average PE of 22.0x (estimated from sector data), Quest Diagnostics trades at an 11% discount, which may be justified by its lower growth profile relative to faster-growing diagnostic peers. The PEG ratio of 1.43x suggests the stock is fairly valued relative to its earnings growth rate. Historically, the stock's PE has ranged from roughly 6.5x (mid-2021) to 44x (end-2022), with the current 19.6x near the lower end of its 5-year range. This suggests the stock is not overvalued relative to its own history, and the current multiple reflects a normalization after pandemic-era volatility. The price-to-book ratio of 2.69x is below the 5-year average of around 2.8x, further supporting a fair valuation.
PE
19.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~22x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Quest Diagnostics carries a debt-to-equity ratio of 0.96, which is manageable but not conservative. Interest expense of $63 million in Q1 2026 represents about 15.8% of operating income, a moderate burden. The company's net margin of 8.7% is thin, leaving little room for error if volumes decline or costs rise. Revenue concentration in clinical testing (over 97%) exposes the firm to reimbursement risk from Medicare and private payers. Free cash flow of $1.326B TTM is strong, but any disruption in collections could pressure the dividend (payout ratio 35.6%).
Market & Competitive Risks: With a beta of 0.571, DGX is less sensitive to macro swings, but it is not immune. Valuation compression is a risk if the PE multiple (19.56x) contracts toward the 5-year low of 6.5x, though that extreme seems unlikely. Competitive threats from hospital outreach labs and new entrants like Exact Sciences could pressure volumes. Regulatory headwinds, such as changes to the Protecting Access to Medicare Act (PAMA), could reduce reimbursement rates. The stock's 25.27% one-year gain already reflects positive sentiment, leaving less room for upside surprise.
Worst-Case Scenario: A severe recession could reduce healthcare utilization, causing revenue growth to stall or decline. Combined with reimbursement cuts, margins could compress. In such a scenario, the stock could fall to the 52-week low of $165.30, representing a -21.5% decline from the current price of $210.68. The analyst low target of $184.00 implies a -12.7% downside. Historical max drawdown of -11.94% suggests a more moderate risk, but a perfect storm of macro and regulatory headwinds could exceed that.
FAQ
The key risks are: 1) Reimbursement risk: Changes to Medicare or private payer rates could compress margins; PAMA cuts are a recurring threat. 2) Volume risk: An economic downturn could reduce healthcare utilization, slowing revenue growth. 3) Competitive risk: Hospital outreach labs and new entrants like Exact Sciences could erode market share. 4) Valuation risk: The stock is near its 52-week high, leaving limited near-term upside. The short ratio of 4.23 days indicates elevated bearish sentiment, reflecting these concerns.
The 12-month forecast is moderately bullish. The base case (50% probability) sees the stock trading between $205 and $225, in line with the average analyst target of $223.94, assuming 7-9% revenue growth and stable margins. The bull case (25% probability) targets $220-$245, driven by accelerating growth and margin expansion. The bear case (25% probability) sees the stock falling to $165-$200, if growth decelerates or reimbursement cuts materialize. The most likely scenario is the base case, with the stock grinding higher as earnings grow.
Quest Diagnostics appears fairly valued to slightly undervalued. Its trailing PE of 19.56x is below the industry average of 22.0x and near the lower end of its 5-year range (6.5x-44x). The PEG ratio of 1.43x suggests the stock is priced in line with its expected earnings growth. The price-to-book ratio of 2.69x is below the 5-year average of ~2.8x. The market is pricing in modest growth, which is consistent with the company's mid-single-digit revenue trajectory. Given the strong free cash flow yield of 6.9%, the stock offers a margin of safety.
Quest Diagnostics is a good buy for investors seeking steady, defensive growth with a reasonable valuation. The stock trades at a trailing PE of 19.56x, an 11% discount to the industry average of 22.0x, and offers a free cash flow yield of 6.9%. Analyst consensus is Buy with an average target of $223.94, implying 6.3% upside. The primary downside risk is a deceleration in revenue growth or reimbursement cuts, which could push the stock to the low target of $184. For long-term investors, the combination of an aging population, expanding test menu, and strong cash flows provides a solid risk/reward. However, near-term upside is limited given the stock is near its 52-week high.
Quest Diagnostics is better suited for long-term investment. Its low beta (0.571), steady revenue growth, and consistent free cash flow make it a reliable compounder. The dividend yield of 1.83% adds a total return component. Short-term trading is less attractive given the stock's low volatility and limited near-term upside from current levels. A minimum holding period of 3-5 years is recommended to capture the benefits of demographic trends and margin expansion. The stock is ideal for a core healthcare holding in a diversified portfolio.